Cannabidiol and Delta-9-Tetrahydrocannabinol Interactions in Male and Female Rats With Persistent Inflammatory Pain
- 16 September 2022
- journal article
- research article
- Published by Elsevier in The Journal of Pain
- Vol. 24 (1) , 98-111
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Institute on Drug Abuse (T32DA035200)
- Washington State University
This publication has 65 references indexed in Scilit:
- Ambulatory Diagnosis and Treatment of Nonmalignant Pain in the United States, 2000–2010Medical Care, 2013
- Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related PainJournal of Pain and Symptom Management, 2010
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- Cannabidiol reverses the reduction in social interaction produced by low dose Δ9-tetrahydrocannabinol in ratsPharmacology Biochemistry and Behavior, 2009
- Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trialClinical Therapeutics, 2007
- Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonistPain, 2006
- Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain modelsEuropean Journal of Neuroscience, 2003
- Interactions between the CB1 receptor agonist Δ9-THC and the CB1 receptor antagonist SR-141716 in ratsPharmacology Biochemistry and Behavior, 2002
- Gender variations in clinical pain experiencePain, 1996
- Open-field behavior and acquisition of discriminative response control in Δ9-THC tolerant ratsCellular and Molecular Life Sciences, 1973